p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cell

• Publication date

  2014-07-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cell.2014.05.051PMID 25083869PMCID PMC4221237
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dedifferentiation of committed epithelial cells into stem cells in vivo

  2013cited by this paper
• Involvement of intermediate filament nestin in cell growth of small-cell lung cancer.

  2013cited by this paper
• Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target

  2013cited by this paper
• Non-cell-autonomous tumor suppression by p53.

  2013cited by this paper
• Regulation of p53 is critical for vertebrate limb regeneration

  2013cited by this paper
• Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties.

  2013cited by this paper
• Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts.

  2013cited by this paper
• Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors

  2012cited by this paper
• Cholangiocarcinomas can originate from hepatocytes in mice.

  2012cited by this paper
• A restricted cell population propagates glioblastoma growth following chemotherapy

  2012cited by this paper
• Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

  2012cited by this paper
• Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease

  2012cited by this paper
• Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation.

  2012cited by this paper
• Deregulation of Hippo kinase signalling in Human hepatic malignancies

  2012cited by this paper
• The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence.

  2012cited by this paper
• Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes.

  2012cited by this paper
• Dedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice

  2012cited by this paper
• p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome.

  2011cited by this paper
• Resource A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference

  2011cited by this paper
• Inducible expression of stem cell associated intermediate filament nestin reveals an important role in glioblastoma carcinogenesis

  2011cited by this paper
• Regeneration in plants and animals: dedifferentiation, transdifferentiation, or just differentiation?

  2011cited by this paper
• Molecular classification of prostate cancer using curated expression signatures

  2011cited by this paper
• Genetics of Hepatobiliary Carcinogenesis

  2011cited by this paper
• Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression.

  2011cited by this paper
• In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models.

  2010cited by this paper
• Nestin expression in human tumors and tumor cell lines.

  2010cited by this paper
• Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures

  2010cited by this paper
• Locating the stem cell niche and tracing hepatocyte lineages in human liver

  2009cited by this paper
• Blinded by the Light: The Growing Complexity of p53.

  2009cited by this paper
• Linking the p53 tumor suppressor pathway to somatic cell reprogramming

  2009cited by this paper
• Direct cell reprogramming is a stochastic process amenable to acceleration

  2009cited by this paper
• Suppression of induced pluripotent stem cell generation by the p53–p21 pathway

  2009cited by this paper
• A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity

  2009cited by this paper
• Regulation of Sp1 by cell cycle related proteins

  2008cited by this paper
• Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression.

  2008cited by this paper
• TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer

  2007cited by this paper
• p53 in health and disease

  2007cited by this paper
• Elucidation of a universal size-control mechanism in Drosophila and mammals.

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection

  2007cited by this paper
• Functional analysis of two Sp1/Sp3 binding sites in murine Nanog gene promoter

  2006cited by this paper
• A nestin scaffold links Cdk5/p35 signaling to oxidant‐induced cell death

  2006cited by this paper
• Liver stem cells and their implication in hepatocellular and cholangiocarcinoma

  2006cited by this paper
• Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

  2006cited by this paper
• Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.

  2006cited by this paper
• p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression

  2005cited by this paper
• Expression of nestin–green fluorescent protein transgene marks oval cells in the adult liver

  2005cited by this paper
• Characterization and promoter analysis of the mouse nestin gene

  2004cited by this paper
• A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

  2004cited by this paper
• Neural stem and progenitor cells in nestin‐GFP transgenic mice

  2004cited by this paper
• Transcriptional repression mediated by the p53 tumour suppressor

  2003cited by this paper
• A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

  2002cited by this paper
• Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system

  2000cited by this paper
• Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.

  2000cited by this paper
• Cellular senescence: mitotic clock or culture shock?

  2000cited by this paper
• Cellular senescence: mitotic clock or culture shock?

  2000cited by this paper
• A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation

  1996cited by this paper
• Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells.

  1994cited by this paper
• Screening for p53 mutations in c3h/he mouse liver tumors derived spontaneously or induced with diethylnitrosamine or phenobarbitone

  1994cited by this paper
• p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts.

  1991cited by this paper

• Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS.

  2026cites this paper
• Oncogenesis in cholangiocarcinoma.

  2026cites this paper
• Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies

  2025cites this paper
• Integrated in vivo combinatorial functional genomics and spatial transcriptomics of tumours to decode genotype-to-phenotype relationships

  2025cites this paper
• Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumorigenesis

  2025influential citation
• Kinase suppressor of Ras 1 (KSR1) promotes liver carcinogenesis via activation of the RAS/RAF/MEK/ERK signaling pathway

  2025cites this paper
• Nestin in multiple myeloma: emerging insights into a potential therapeutic target

  2025cites this paper
• The rise of RAS: how gradual oncogene activation shapes the OIS spectrum

  2025cites this paper
• Other Primary Epithelial Neoplasms of the Liver.

  2025cites this paper
• To be or not to be (a biliary cancer): RAS (signalling) is the question

  2025cites this paper
• Tumor Cell Plasticity in Cancer: Signaling Pathways and Pharmaceutical Interventions

  2025cites this paper
• Cancer stem cells in hepatocellular carcinoma: therapy resistance and emerging treatments

  2025cites this paper
• Translating Basic Science Discoveries into Clinical Advances: Highlights from the EACR-AACR-IACR 2024 Conference in Celebration of Irish Association for Cancer Research’s 60th Anniversary

  2025cites this paper
• Epigenetically regulated p53 activity maintains intestinal regulatory T cell identity to prevent inflammation

  2025cites this paper
• Role of immunotherapies and stem cell therapy in the management of liver cancer: A comprehensive review.

  2024cites this paper
• Integrated combinatorial functional genomics and spatial transcriptomics of tumors decodes genotype to phenotype relationships

  2024cites this paper
• Understanding the complexity of p53 in a new era of tumor suppression.

  2024cites this paper
• Machine Learning Reveals Aneuploidy Characteristics in Cancers: The Impact of BEX4.

  2024cites this paper
• Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumourigenesis

  2024cites this paper
• ZMAT2 condensates regulate the alternative splicing of TRIM28 to reduce cellular ROS accumulation, thereby promoting the proliferation of HCC cells

  2024cites this paper
• Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review

  2024cites this paper
• YTHDF3-mediated m6A modification of NKD1 regulates hepatocellular carcinoma invasion and metastasis by activating the WNT/β-catenin signaling axis.

  2024cites this paper
• Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study

  2024cites this paper
• Hallmarks of cancer stemness.

  2024cites this paper
• The molecular determinants of phenotypic plasticity in homeostasis and neoplasia

  2024cites this paper
• Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets

  2024cites this paper
• Titration of RAS alters senescent state and influences tumour initiation

  2024cites this paper
• FOXM1/DEPDC1 feedback loop promotes hepatocarcinogenesis and represents promising targets for cancer therapy

  2024cites this paper
• p53 mutation biases squamocolumnar junction progenitor cells towards dysplasia rather than metaplasia in Barrett’s oesophagus

  2024cites this paper
• Ovarian Microcystic Stromal Tumor with Significant Nestin Expression: A Unique Case

  2024cites this paper
• Morphomolecular pathology and Genomic Insights into the Cells of Origin of Cholangiocarcinoma and combined Hepatocellular-Cholangiocarcinoma.

  2024cites this paper
• Regulation of Tumor Vascular Microenvironment by Nestin and Fms-related Tyrosine Kinase 1 (FLT1) and Their Prognostic Significance in Renal Cell Carcinoma

  2024cites this paper
• BET inhibition induces GDH1-dependent glutamine metabolic remodeling and vulnerability in liver cancer

  2024cites this paper
• A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy

  2023cites this paper
• Sirtuin1-p53: a potential axis for cancer therapy.

  2023cites this paper
• Atractylodin and β-eudesmol from Atractylodes lancea (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway

  2023cites this paper
• Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management

  2023cites this paper
• Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

  2023cites this paper
• p53 governs an AT1 differentiation programme in lung cancer suppression

  2023cites this paper
• Update on Hepatobiliary Plasticity

  2023cites this paper
• Multifaceted role for p53 in pancreatic cancer suppression

  2023cites this paper
• MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer

  2023cites this paper
• Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.

  2023cites this paper
• Be mindful of potential pitfalls when using the Cre-LoxP system in cancer research

  2023cites this paper
• The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance

  2023cites this paper
• Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

  2023cites this paper
• From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification

  2023influential citation
• Cellular Origins and Lineage Plasticity in Cancer.

  2023cites this paper
• Natural killer cell therapy targeting cancer stem cells: Old wine in a new bottle.

  2023cites this paper
• Distribution, contribution and regulation of nestin+ cells

  2023cites this paper
• Current view of liver cancer cell-of-origin and proposed mechanisms precluding its proper determination

  2023cites this paper
• 2-(4-Benzyloxy-3-methoxyphenyl)-5-(carbethoxyethylene)-7-methoxy-benzofuran, a Benzofuran Derivative, Suppresses Metastasis Effects in P53-Mutant Hepatocellular Carcinoma Cells

  2023cites this paper
• Nestin Expression and the Survival of Patients With Digestive Tract Cancers: A Systematic Review and Meta-Analysis

  2023cites this paper
• Fibroblast-derived lysyl oxidase increases oxidative phosphorylation and stemness in cholangiocarcinoma.

  2023cites this paper
• Nestin overexpression reduces the sensitivity of gastric cancer cells to trastuzumab

  2023cites this paper
• TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression

  2022cites this paper
• Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development

  2022cites this paper
• Cell origin, biology, and pathophysiology of hepatocellular carcinoma

  2022cites this paper
• Emerging biomarker in carcinogenesis. Focus on Nestin

  2022cites this paper
• The chameleonic behavior of p53 in health and disease: the transition from a client to an aberrant condensate scaffold in cancer.

  2022cites this paper
• Miat and interacting protein Metadherin maintain a stem-like niche to promote medulloblastoma tumorigenesis and treatment resistance

  2022cites this paper
• Nestin protein affects the maintenance of stem characteristics of colorectal cancer cells based on p53 dependent pathway

  2022cites this paper
• YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.

  2022cites this paper
• Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.

  2022cites this paper
• Notch signaling in the pathogenesis, progression and identification of potential targets for cholangiocarcinoma (Review)

  2022cites this paper
• Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression

  2022cites this paper
• Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53

  2022cites this paper
• Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU via TCF21/CD44 Axis-Mediated Enhanced Stemness in Colorectal Carcinoma

  2022cites this paper
• Is nestin a diagnostic marker for combined hepatocellular–cholangiocarcinoma?

  2022influential citation
• MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer

  2022cites this paper
• A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets

  2022cites this paper
• Cellular and molecular mechanisms of plasticity in cancer.

  2022cites this paper
• Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma

  2022cites this paper
• The ascending aorta of male hypertensive bicuspid aortic valve patients preferentially associated with a cellular aneurysmal phenotype

  2022cites this paper
• Phenotypic plasticity during metastatic colonization.

  2022cites this paper
• DNA methylation profiling identifies subgroups of lung adenocarcinoma with distinct immune cell composition, DNA methylation age, and clinical outcome.

  2022cites this paper
• The immunological and metabolic landscape in primary and metastatic liver cancer

  2021cites this paper
• Nestin Expression as a Diagnostic and Prognostic Marker in Colorectal Cancer and Other Tumors

  2021cites this paper
• Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach

  2021cites this paper
• Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice

  2021cites this paper
• Nestin-Expressing Cells in the Lung: The Bad and the Good Parts

  2021cites this paper
• Combined hepatocellular-cholangiocarcinoma: An update.

  2021cites this paper
• Development of human iPSC-derived quiescent hepatic stellate cell-like cells for drug discovery and in vitro disease modeling

  2021cites this paper
• miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC

  2021cites this paper
• Liver Inflammation and Hepatobiliary Cancers.

  2021cites this paper
• Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver

  2021cites this paper
• Cancer Stemness: p53 at the Wheel

  2021cites this paper
• Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

  2021cites this paper
• TAp73β Can Promote Hepatocellular Carcinoma Dedifferentiation

  2021cites this paper
• Cell of origin in biliary tract cancers and clinical implications

  2021cites this paper
• RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence

  2021cites this paper
• Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications

  2021cites this paper
• p53-Dependent Repression: DREAM or Reality?

  2021cites this paper
• PIM1 Inhibition Affects Glioblastoma Stem Cell Behavior and Kills Glioblastoma Stem-like Cells

  2021cites this paper
• Involvement of Felis catus papillomavirus type 2 in the tumorigenesis of feline Merkel cell carcinoma

  2021cites this paper
• Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer

  2021cites this paper
• Nestin is essential for cellular redox homeostasis and gastric cancer metastasis through the mediation of the Keap1–Nrf2 axis

  2021cites this paper
• LncRNA Miat and Metadhedrin maintain a treatment resistant stem-like niche of medulloblastoma cells

  2021cites this paper
• Bladder cancer cells prevent cisplatin-induced oxidative stress by upregulating Nestin1 expression.

  2021cites this paper
• Nestin Is Required for Spindle Assembly and Cell-Cycle Progression in Glioblastoma Cells

  2021cites this paper